Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral ...
Orforglipron, a once-daily pill, has outperformed oral semaglutide in a phase 3 clinical trial, showing greater efficacy in managing blood sugar levels and promoting weight loss.
MedPage Today on MSN
What One Adderall Pill Does to the Heart Within Hours of Use
Significant blood pressure, heart rate effects shown in placebo-controlled trial ...
The Matrix 5 finally gets a promising update 5 years after the last film in the franchise hit theaters. See what ...
Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...
It looks like Apple isn’t the only company with new products launching soon. A new Sonos Play portable Bluetooth ...
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
Daemon—the rapping rock star with a voice built for both confession and combustion—brought lyrical lightning to The Dark Room on Saturday night. He debuted “Euphonic (Deluxe),” a reimagined version of ...
Trump’s proposed ACA plans carry sky-high deductibles; Rare disease advocates fume over the FDA’s mixed signals; Cardiovascular disease on the rise among young women.
The fast-food chain’s shareholders voted to re-elect all 10 directors, beating back a “vote no” effort on Chairman David ...
Wegovy generated DKK 79.1 billion in net revenues for Novo Nordisk in 2025, a 35.9% increase year-on-year. Learn why NVO stock is a strong buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results